DOP2002000431A - Vacunación en dosis unica con mycoplasma hyopneumoniae - Google Patents

Vacunación en dosis unica con mycoplasma hyopneumoniae

Info

Publication number
DOP2002000431A
DOP2002000431A DO2002000431A DO2002000431A DOP2002000431A DO P2002000431 A DOP2002000431 A DO P2002000431A DO 2002000431 A DO2002000431 A DO 2002000431A DO 2002000431 A DO2002000431 A DO 2002000431A DO P2002000431 A DOP2002000431 A DO P2002000431A
Authority
DO
Dominican Republic
Prior art keywords
vaccine
hyo
mycoplasma hyopneumoniae
dose vaccination
present
Prior art date
Application number
DO2002000431A
Other languages
English (en)
Inventor
Robin Lee Keich
Lise Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2002000431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2002000431A publication Critical patent/DOP2002000431A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/87Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a procedimientos para el tratamiento o prevención de una enfermedad o trastorno en un animal causada por infección por Mycoplasma hyopneumoniae M. hyo mediante la administración a un animal, a aproximadamente los tres 3 a diez 10 días de edad, de una dosis única de una cantidad efectiva de una vacuna de M. hyo. La vacuna de M. hyo puede ser una preparación de células vivas modificadas o de células inactivadas parcial o . completamente, una vacuna de subunidades o una vacuna de ácido nucleico o ADN. La vacuna de M. hyo administrada de acuerdo con la presente invención puede producirse de manera sintética o recombinante.
DO2002000431A 2001-07-02 2002-06-26 Vacunación en dosis unica con mycoplasma hyopneumoniae DOP2002000431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
DOP2002000431A true DOP2002000431A (es) 2003-01-15

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000431A DOP2002000431A (es) 2001-07-02 2002-06-26 Vacunación en dosis unica con mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (es)
EP (3) EP1474067B2 (es)
JP (1) JP2005515162A (es)
KR (1) KR20040030785A (es)
CN (3) CN1551781B (es)
AP (1) AP2003002937A0 (es)
AR (1) AR034678A1 (es)
AT (1) ATE412426T2 (es)
AU (1) AU2002309109B2 (es)
BG (1) BG66481B1 (es)
BR (1) BR0210804A (es)
CA (1) CA2451626C (es)
CY (1) CY1108749T1 (es)
CZ (1) CZ305781B6 (es)
DE (1) DE60229666D1 (es)
DK (3) DK1474067T4 (es)
DO (1) DOP2002000431A (es)
EA (1) EA009901B1 (es)
ES (3) ES2312580T5 (es)
GT (1) GT200200138A (es)
HK (4) HK1068250A1 (es)
HR (1) HRP20031079A2 (es)
HU (1) HU230246B1 (es)
IL (1) IL159349A0 (es)
IS (1) IS7076A (es)
MA (1) MA27047A1 (es)
MX (1) MXPA03011599A (es)
NO (1) NO342654B1 (es)
NZ (1) NZ530106A (es)
OA (1) OA12638A (es)
PA (1) PA8549701A1 (es)
PE (1) PE20030285A1 (es)
PL (1) PL209773B1 (es)
PT (3) PT2027873E (es)
SK (1) SK288010B6 (es)
TN (1) TNSN03155A1 (es)
TW (1) TWI329514B (es)
UA (1) UA78707C2 (es)
UY (1) UY27366A1 (es)
WO (1) WO2003003941A2 (es)
YU (1) YU102203A (es)
ZA (1) ZA200309698B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (en) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Multiple-strain mycoplasma hyopneumoniae vaccines
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP2371382B1 (en) 2005-12-29 2016-03-02 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
CN101448521A (zh) * 2006-03-03 2009-06-03 梅瑞尔有限公司 猪肺炎支原体疫苗
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
KR101619730B1 (ko) 2006-12-15 2016-05-12 베링거잉겔하임베트메디카인코퍼레이티드 Pcv2 항원을 이용한 돼지의 치료
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
UA98812C2 (ru) * 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
KR20100103535A (ko) * 2007-12-31 2010-09-27 베링거잉겔하임베트메디카인코퍼레이티드 외래 아미노산 삽입물을 갖는 pcv2 orf2 바이러스 유사 입자
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Pcv2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
ES2569907T3 (es) * 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
CA2764424C (en) 2009-06-04 2019-12-31 National Institute Of Advanced Industrial Science And Technology Vaccine for mycoplasma infection
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011141443A1 (en) 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
CN103140238B (zh) * 2010-07-26 2016-03-16 Qu生物制药公司 免疫原性抗炎组合物
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
DK2609428T3 (en) * 2010-08-27 2016-05-17 Intervet Int Bv STRENGTH TEST FOR VACCINE FORMULATIONS
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112014022067B1 (pt) * 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
MX2015007729A (es) 2012-12-28 2015-09-07 Boehringer Ingelheim Vetmed Composicion inmunogenica que comprende antigenos de mycoplasma.
EP2938747B1 (en) 2012-12-28 2019-05-01 Boehringer Ingelheim Vetmedica GmbH Method of making a mycoplasma vaccine
WO2014121433A1 (zh) * 2013-02-05 2014-08-14 财团法人农业科技研究院 抗霉浆菌的亚单位疫苗
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
CN109675029A (zh) 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
MX2016004063A (es) 2013-10-02 2016-06-06 Boehringer Ingelheim Vetmed Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
DK3072523T3 (en) * 2013-11-21 2019-04-08 Agricultural Tech Res Inst COMPOSITION FOR PREVENTION AND TREATMENT OF INFECTIONS WITH MYCOPLASMA
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
HUE063288T2 (hu) 2015-01-16 2024-01-28 Zoetis Services Llc Száj és körömfájás betegség vakcina
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
KR101846478B1 (ko) * 2016-08-12 2018-04-06 주식회사 이노백 재조합 단백질을 포함하는 돼지 마이코플라즈마 감염 예방용 백신 조성물
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
DE3881993T2 (de) 1987-09-18 1993-09-30 Akzo Nv Mycoplasma-Impfstoff.
CA2078131A1 (en) 1990-04-02 1991-10-03 Jerry M. Kuner Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
WO1991018627A1 (en) * 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (en) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. DNA's encoding surface antigen of mycoplasma hyopneumoniae, DNA fragments for primer, recombinant antigenic peptides and diagnostic method of mycoplasmal pneumoniae of swine using same
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
ES2225825T3 (es) * 1992-09-28 2005-03-16 Wyeth Holdings Corporation Procedimiento de mejora de las respuestas inmunitarias mediadas por celulas.
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (en) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. Characterization of mycoplasma hyopneumoniae adhesins
PT1820512E (pt) 1994-05-10 2013-10-09 Boehringer Ingelheim Vetmed Vacina viva modificada melhorada contra brsv
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
JP4113588B2 (ja) 1996-09-30 2008-07-09 ユニヴァーシティ・オヴ・アーカンサス ワクチン結合物を用いて免疫活性を産生する方法
EP0846468B1 (en) 1996-12-05 2004-06-09 Akzo Nobel N.V. Non-virulent mycoplasma synoviae and vaccine thereof
HUP0100130A2 (hu) 1997-11-26 2001-05-28 Iowa State University Research Foundation, Inc. Rekombináns Mycoplasma hyopneumoniae vakcina
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
UY27366A1 (es) 2003-04-30
IL159349A0 (en) 2004-06-01
ES2312580T5 (es) 2017-12-11
BR0210804A (pt) 2005-05-03
ES2312580T3 (es) 2009-03-01
MA27047A1 (fr) 2004-12-20
EP2027873B8 (en) 2015-11-11
UA78707C2 (en) 2007-04-25
EA200301323A1 (ru) 2005-06-30
PL373367A1 (en) 2005-08-22
DK2027873T3 (en) 2015-11-09
BG108546A (bg) 2005-02-28
IS7076A (is) 2003-12-15
CN102872456A (zh) 2013-01-16
HUP0400434A2 (en) 2007-08-28
CN1551781B (zh) 2013-01-02
EP1474067A2 (en) 2004-11-10
NO342654B1 (no) 2018-06-25
EP2027873A1 (en) 2009-02-25
CA2451626C (en) 2011-05-31
AP2003002937A0 (en) 2003-12-31
HU230246B1 (hu) 2015-11-30
OA12638A (en) 2006-06-15
US6846477B2 (en) 2005-01-25
CZ305781B6 (cs) 2016-03-16
NO20035762L (no) 2004-02-02
PL209773B1 (pl) 2011-10-31
CN1551781A (zh) 2004-12-01
HK1180224A1 (zh) 2013-10-18
ES2550458T3 (es) 2015-11-10
KR20040030785A (ko) 2004-04-09
ZA200309698B (en) 2014-04-30
CA2451626A1 (en) 2003-01-16
SK288010B6 (sk) 2012-10-02
AU2002309109B2 (en) 2007-12-13
WO2003003941A2 (en) 2003-01-16
BG66481B1 (bg) 2015-02-27
PE20030285A1 (es) 2003-03-27
AR034678A1 (es) 2004-03-03
EP2842569A1 (en) 2015-03-04
PT2027873E (pt) 2015-11-03
ATE412426T2 (de) 2008-11-15
CN101524532A (zh) 2009-09-09
DK1474067T3 (da) 2008-12-08
DK2842569T3 (da) 2019-05-20
GT200200138A (es) 2003-05-15
PA8549701A1 (es) 2003-01-24
HK1207584A1 (en) 2016-02-05
EP1474067A4 (en) 2005-08-10
ES2729579T3 (es) 2019-11-04
EP2842569B1 (en) 2019-04-10
NZ530106A (en) 2007-06-29
CY1108749T1 (el) 2014-04-09
DE60229666D1 (de) 2008-12-11
MXPA03011599A (es) 2005-03-07
SK15792003A3 (sk) 2005-09-08
PT2842569T (pt) 2019-06-17
CN101524532B (zh) 2014-03-19
USRE44399E1 (en) 2013-07-30
PT1474067E (pt) 2008-11-14
WO2003003941A3 (en) 2004-07-29
TWI329514B (en) 2010-09-01
HK1134900A1 (en) 2010-05-20
HK1068250A1 (en) 2005-04-29
EP1474067B2 (en) 2017-08-16
CN102872456B (zh) 2016-01-20
YU102203A (sh) 2006-05-25
EA009901B1 (ru) 2008-04-28
US20030109473A1 (en) 2003-06-12
TNSN03155A1 (fr) 2005-12-23
DK1474067T4 (en) 2017-10-16
JP2005515162A (ja) 2005-05-26
EP1474067B1 (en) 2008-10-29
EP2027873B1 (en) 2015-09-09
HRP20031079A2 (en) 2005-10-31
US20050013823A1 (en) 2005-01-20
CZ20033466A3 (cs) 2005-06-15

Similar Documents

Publication Publication Date Title
DOP2002000431A (es) Vacunación en dosis unica con mycoplasma hyopneumoniae
AR034677A1 (es) Vacuna de mycoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado
UY27365A1 (es) Vacuna de mycoplasma bovis y métodos para reducir la neumonía en animales
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
ES2118815T3 (es) Virus de la seudorrabia, s-prv-155, atenuado y obtenido por ingenieria genetica y sus usos.
BRPI0010612B8 (pt) vacinas
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
AR054844A1 (es) Vacuna contra lawsonia y metodos de uso de la misma
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
JP2003513935A5 (es)
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
RU2010120324A (ru) Вакцина против вируса синего языка и иммуногенные композиции, способы их применения и способы их получения
AR053661A1 (es) Peptido para entregar vacunas via mucosas
AR048671A1 (es) Procedimiento de vacunacion contra la infeccion testicular por bvdv
AR036355A1 (es) Modelo de exposicion a mycoplasma bovis, para evaluar la eficacia de potenciales vacunas
JP3701304B2 (ja) 皮膚糸状菌症用ワクチン
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
AR056753A1 (es) Vacuna de primera dosis -refuerzo para la proteccion de equinos contra la influenza equina
HN2002000163A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
CY1116862T1 (el) Εμβολιασμος μιας δοσης me mycoplasma hyopneumoniae
RU2213573C2 (ru) Способ профилактики паратифа телят
TH64472A (th) การให้วัคซีนขนาดยาเดียวที่มี Mycoplasma Hyopneumoniae
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
UA57299A (uk) Спосіб виготовлення вакцини проти вірусної геморагічної хвороби кролів